雙成藥業(002693.SZ):公司藥品生產許可證變更 新增生產範圍大容量注射劑
格隆匯 3 月 16日丨雙成藥業(002693.SZ)公佈,公司近日取得海南省藥品監督管理局下發的《藥品生產許可證》。此次主要涉及生產範圍的變更,新增生產範圍:大容量注射劑。
生產地址和生產範圍:海口市秀英區興國路16號;原料藥(胸腺法新,艾塞那肽,比伐蘆定、依替巴肽、胸腺五肽、生長抑素、醋酸曲普瑞林),凍乾粉針劑(三車間、四車間),小容量注射劑(含卡式),大容量注射劑***。
此次《藥品生產許可證》涉及生產範圍的變更,有利於未來豐富公司產品的結構,更好滿足市場需求。短期內對公司業績無重大影響,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.